Source: International Congress 2019 – Environment, work and respiratory health in occupational and environmental lung diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Sánchez-Díez (Barcelona, Spain), M. Cruz (Barcelona, Spain), M. De Homdedeu (Barcelona, Spain), I. Ojanguren (Barcelona, Spain), C. Romero-Mesones (Barcelona, Spain), A. Villar (Barcelona, Spain), X. Muñoz (Barcelona, Spain). YKL-40 and KL-6 in serum and sputum samples of patients diagnosed with hypersensitivity pneumonitis.. 2818

Member's Comments

No comment yet.

Related content which might interest you: Levels of YKL-40 in serum and sputum of patients diagnosed with hypersensitivity pneumonitis: A pilot study. Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis:  mechanistic insights and prognostic markers Year: 2018 Serum concentrations of KL-6 in patients with IPF and lung cancer and serial measurements of KL-6 in IPF patients treated with antifibrotic therapy Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Serum KL-6 level is increased in patients with pneumocystis pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 101s Year: 2006 Serum ECP in comparison to sputum ECP measurements in symptomatic and asymptomatic subjects with asthma Source: Eur Respir J 2001; 18: Suppl. 33, 335s Year: 2001 Serum KL-6 elevation related with severity in patients with pneumocystis pneumonia Source: Annual Congress 2011 - Infection in the immunocompromised host: infrequent aetiologies Year: 2011 Comparative study of CC16, KL-6 and SP-D as serum markers in sarcoid patients Source: Eur Respir J 2002; 20: Suppl. 38, 173s Year: 2002 Serum KL-6 identifies ILD patients with a progressive fibrosing phenotype Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis Source: Eur Respir J , 49 (2) 1501924; DOI: 10.1183/13993003.01924-2015 Year: 2017 CEA levels in the serum and induced sputum of lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005 Serum KL-6, SP-D and MMP-2 as diagnostic biomarkers in asbestosis and silicosis Source: International Congress 2017 – Silicosis has not gone away Year: 2017 Serum YKL-40 modulation in severe asthma patients treated with Mepolizumab Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Elevated levels of BALF galectin-9 in patients with interstitial pneumonia Source: Annual Congress 2009 - Airways remodelling Year: 2009 Overexpression of chitotriosidase and YKL-40 in serum and sputum in healthy smokers and patients with  chronic obstructive pulmonary disease Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018 Induced sputum and BAL from patients with hypersensitivity pneumonitis Source: Eur Respir J 2001; 18: Suppl. 33, 508s Year: 2001 Serum and BAL levels of KL6 in chronic hypersensitivity pneumonitis Serum and BAL levels of KL6 in chronic hypersensitivity pneumonitis Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Serum and BALF levels of YKL-40 in patients with alveolar proteinosis Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 KL-6 serum levels in adult cystic fibrosis patients Source: Annual Congress 2011 - Cystic fibrosis: clinical and laboratory studies Year: 2011 Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Is CRP really valid acute-phase inflammation reactant in all patients with sputum bacterial positive culture in acute exacerbation of COPD? Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010 High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010